Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26683709
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Prognostic value of high EZH2 expression in patients with different types of
cancer: a systematic review with meta-analysis
#MMPMID26683709
Jiang T
; Wang Y
; Zhou F
; Gao G
; Ren S
; Zhou C
Oncotarget
2016[Jan]; 7
(4
): 4584-97
PMID26683709
show ga
Enhancer of zeste homologue 2 (EZH2) is a potential independent mechanism for
epigenetic silencing of tumor suppressor genes in cancer. We conducted an
electronic search on PubMed, EMBASE, Web of Science, and Cochrane library to
perform this up-to-date meta-analysis. Fifty-one studies with a total of 9444
patients were included. The prevalence of high EZH2 expression was 0.54 (95% CI:
0.47-0.61). High EZH2 expression was significantly associated with poorer
prognosis [overall survival: HR 1.54 (95% CI: 1.30-1.78), P < 0.000; disease free
survival: HR 1.35 (95% CI: 1.00-1.71), P < 0.000]. In breast cancer, high EZH2
expression correlated with histological types [OR: 1.53 (95CI: 1.13-2.06); P <
0.006], histological grade [OR: 1.62 (95CI: 1.35-1.95); P < 0.000], estrogen
receptor (ER) negativity [OR: 2.05 (95CI: 1.67-2.52); P < 0.000], progesterone
receptor (PgR) negativity [OR: 1.42 (95CI: 1.03-1.96); P = 0.034], HER-2
positivity [OR: 1.35 (95CI: 1.08-1.69); P = 0.009], and high p53 expression [OR:
1.66 (95CI: 1.07-2.59); P = 0.024]. These results suggest that high EZH2
expression may be a promising prognostic factor to different cancers. High EZH2
expression tends to correlate with pathological types, histological grade, ER
negativity, PgR negativity, HER-2 positivity and p53 high expression in breast
cancer.
free
free
free
